The CD38-targeted construct successfully restored the functionality of dysfunctional NK cells, resulting in the elimination of CD38+ multiple myeloma cells and significant tumor growth inhibition in mouse models (97). The gene discussed is CD38; the disease is plasma cell myeloma.